Causaly Secures $60M Funding to Drive AI-Driven Drug Discovery

Causaly, a leading artificial intelligence (AI) technology provider in the healthcare sector, announced today that it has secured Series B funding of $60 million to drive drug discovery. The funding was led by Mubadala Capital, with participation from WIP hive, Vardy Ventures, Dreamit, and other venture capital firms.

This latest round of financing will enable Causaly to accelerate the development of its AI-driven drug discovery platform and further enhance the technology to accelerate the discovery of more targeted treatments and clinical interventions.

The primary focus of Causaly’s drug discovery platform is disease-specific research. It utilizes comprehensive search techniques, ontology-based text analysis, and predictive models to identify previously unknown information, thereby aiding drug developers in the development of more targeted treatments for a variety of diseases.

Causaly has achieved considerable success in the healthcare industry since its inception in 2018, receiving numerous industry awards for its work in creating solutions to facilitate the drug discovery process. The company has established key partnerships in the health and wellness, biotech, and pharmaceutical spaces to ensure the continued development of its platform.

According to the founder and CEO of Causaly, Seyed Reza Mousavi, “The new funds will further enable us to continue to build on our existing success and accelerate our drug discovery platform development. Our mission is to make drug discovery faster, cheaper and more successful by using AI-driven methods to provide new insights into disease. We view this as an important tool to help the industry develop better treatments in a more timely manner.”

The new funding will allow Causaly to continue advancing its platform’s capabilities, both on the technology side and through partnerships, and to create solutions that have the potential to revolutionize drug discovery.

Causaly is well-positioned to play a major role in the industry as its platform continues to evolve. With the company’s commitment to its mission and this latest round of funding, it is poised to make further strides over the coming years.